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ABSTRACT: Here, we demonstrate a supramolecular
latching tool for bio-orthogonal noncovalent anchoring of
small synthetic molecules in live animal models using a fully
synthetic high-affinity binding pair between cucurbit[7]uril
(CB[7]) and adamantylammonium (AdA). This supra-
molecular latching system is small (∼1 kDa), ensuring
efficient uptake into cells, tissues, and whole organisms. It is
also chemically robust and resistant to enzymatic degradation
and analogous to well-characterized biological systems in
terms of noncovalent binding. Occurrence of fluorescence
resonance energy transfer (FRET) between cyanine 3-CB[7]
(Cy3-CB[7]) and boron-dipyrromethene 630/650X-AdA
(BDP630/650-AdA) inside a live worm (Caenorhabditis
elegans) indicates efficient in situ high-affinity association between AdA and CB[7] inside live animals. In addition, selective
visualization of a cancer site of a live mouse upon supramolecular latching of cyanine 5-AdA (Cy5-AdA) on prelocalized CB[7]-
conjugating antibody on the cancer site demonstrates the potential of this synthetic system for in vivo cancer imaging. These
findings provide a fresh insight into the development of new chemical biology tools and medical therapeutic systems.
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■ INTRODUCTION
In regions of pathogenic bacterial and viral infections in
animals, selective recognition of antigens on bacteria and
viruses by antibodies triggers opsonization of bacteria by
macrophages and neutralization of viruses by blocking active
sites.1,2 Such important in situ biological processes occur
specifically and selectively at infected sites in animals based on
accurate and reliable in situ molecular recognition between
biomolecules in complex and dynamic biological environ-
ments. This molecular recognition feature has been exploited
as a protein-based noncovalent tool to anchor a functionality
to the other materials, providing new functional materials and
tools for bioapplications including targeted drug delivery and
imaging.3−7 However, typical protein-based systems are large
(>100 kDa), thus requiring long treatment durations to
achieve sufficient interaction with their binding partners in
living organisms or fixation of tissues after taking biopsies.8−10
Additionally, enzymatic degradation and difficulty in chemical
modifications limit their uses for broad applications.11
Synthetic binding pair systems can be alternatives for
noncovalent anchoring because they are typically small (∼1
kDa), chemically tractable and scalable, and resistant to
enzymatic degradation. Host−guest chemistry with macro-
cyclic molecules including calixarenes,12,13 cucurbiturils,14,15
cyclodextrins,16−20 and pillararenes21,22 has been extensively
studied, not only to better understand recognition at the
molecular level but also to develop new materials and tools.23
Cyclodextrins and their guests, representing the most well-
studied macrocyclic systems, have great potential as non-
covalent binding pairs in aqueous media, as demonstrated by
host−guest complexes between α-cyclodextrin and polyethy-
leneglycol and between β-cyclodextrin and adamantane/
ferrocene (ßCD-Ad and ßCD-Fc). These binding pairs have
mostly been used as pre-associated forms not dissociated by
forming rotaxanes or that slowly dissociate after being applied
to biological systems such as cells and animals.16−18 Affinity-
based in situ binding of cyclodextrins to their guests has been
demonstrated only under simple conditions such as pure
water;19,20 in situ binding under complex and dynamic
biological conditions has not yet been achieved because of a
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significant reduction in binding fidelity through interference by
other small molecules such as salts and proteins.
Recently, synthetic binding pairs with extremely high
binding affinities have emerged based on cucurbit[7]uril
(CB[7]), a member of a group of synthetic pumpkin-shaped
macrocyclic molecules known as cucurbit[n]urils (n = 5−8, 10,
13−15) comprising n glycouril units with a hydrophobic cavity
accessible through two identical carbonyl portals.24−27 For
example, CB[7] forms host−guest complexes with its selected
guests, including ferrocenemethyl (FcA), adamantyl (AdA),
and diadamantinyl ammonium derivatives, with extremely high
affinity (Ka ≈ 1013 to 1017 M−1)28 comparable to or higher
than that of protein-based high-affinity binding pairs found in
nature such as streptavidin−biotin (Ka ≈ 1013 M−1) and
antibody−antigen (Ka ≈ 108 to 1013 M−1).29 Interestingly, this
high-affinity molecular recognition between CB[7] and its
guests takes place selectively and specifically in situ under
physiological conditions and is not interfered with significantly
by other biological systems, as confirmed by the occurrence of
a fluorescence resonance energy transfer (FRET) signal
between Cy3-CB[7]30,31 and cyanine 5-conjugated AdA
(Cy5-AdA) as the donor and acceptor, respectively, inside
live cells.31 In addition, the CB[7]-based high-affinity bonds
were exploited for protein imaging in cells30 and tissues32 and
to enhance the local concentration of prodrug-conjugated
adamantane (or ferrocene) in a cancer-bearing mouse.33 These
results motivated us to investigate high-affinity in situ host−
guest binding in live animals using clear FRET imaging and
explore the potential application of the former for active
pretargeted in vivo cancer imaging.
Herein, we demonstrate supramolecular latching for tightly
controlled noncovalent anchoring of a small molecule inside a
simple animal model, Caenorhabditis elegans (C. elegans), using
FRET between cyanine 3-conjugated-CB[7] (Cy3-CB[7]) and
boron-dipyrromethene 630/650X-conjugated AdA (BDP630/
650-AdA). Furthermore, we show the promising potential of
this supramolecular latching system for in vivo cancer imaging
by in situ bio-orthogonal anchoring of Cy5-AdA to antibody-
conjugated CB[7] (Erbitux-CB[7]) pretargeted on a cancer
site in a live mouse model (Figure 1).
■ RESULTS AND DISCUSSION
A soil nematode, C. elegans, as a simple animal model was used
in this study before investigating with higher animals such as
mice because it can be safely used in the laboratory and is
inexpensive to cultivate compared with other animals such as
zebrafish and mice. Furthermore, the responses of this
organism to chemicals can be easily visualized by fluorescence
microscopy because of their small size (∼1 mm in length) and
transparent body.34 To visualize in situ high-affinity binding in
worms using confocal laser scanning microscopy (CLSM), we
developed a new high-affinity supramolecular FRET pair
Figure 1. (a) Chemical structures of Cy3-CB[7], antibody-CB[7] (Erbitux-CB[7]), BDP630/650-AdA, and Cy5-AdA, (b) schematic illustration of
locations of high-affinity host−guest interaction in live C. elegans, and (c) in vivo cancer imaging using the high-affinity host−guest interaction
between Erbitux-CB[7] and AdA-Cy5 that are sequentially injected to a cancer-bearing mouse through the tail vein.
Figure 2. (a) Fluorescence emission spectra of Cy3-CB[7] only, BDP630/650-AdA only, and a mixture of Cy3-CB[7] and BDP630/650-AdA in
PBS buffer containing 3% BSA. (Cy3-CB[7]) = [BDP630/650-AdA] = 500 nM. (b) Fluorescence emission spectra of Cy3 only, BDP630/650 only,
and a mixture of Cy3 and BDP630/650 in PBS buffer containing 3% BSA. [Cy3] = [BDP630/650] = 500 nM (excitation at 530 nm).
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consisting of Cy3-CB[7] and BDP630/650-AdA as the donor
and acceptor, respectively (Figure 1). Cy3-CB[7] was
synthesized as described in a previous report.30,31 BDP630/
650-AdA was newly synthesized by coupling N-hydroxysucci-
nimide (NHS)-activated BDP630/650 with an adamantane
amine derivative (AdA; see Experimental Section for the
synthesis). We mixed Cy3-CB[7] with BDP630/650-AdA in
phosphate-buffered saline (PBS) containing 3% bovine serum
albumin (BSA) to mimic the crowded intracellular environ-
ment.35 Upon excitation at 530 nm, the reduced fluorescence
intensity of Cy3-CB[7] (46% at 565 nm) and the enhanced
signal from BDP630/650-AdA (78% at 650 nm) clearly
indicated FRET between the Cy3-CB[7] donor and BDP630/
650-AdA acceptor (Figure 2a, see Experimental Section for the
FRET efficiency). In a control experiment performed with free
dyes (Cy3 and BDP630/650) under the same conditions, we
did not observe a fluorescence change (Figure 2b), confirming
that FRET occurred through the selective molecular
recognition between CB[7] and AdA in a medium containing
proteins.
Using this high-affinity host−guest FRET pair, we first
investigated the innate fate of each FRET component (Cy3-
CB[7] and BDP630/650-AdA) in live C. elegans. Worms were
dosed with each molecule via digestive tract absorption, and
we observed strong fluorescence signals for BDP630/650-AdA
in intestinal cells (Figure 3b) of worms incubated with
BDP630/650-AdA for 6 h before destaining for 12 h (see the
Supporting Information for details). Colocalization analysis
showed good overlap of fluorescence signals from BDP630/
650-AdA and BODIPY 493/503 (Figure S5a), known to stain
lipid droplets in intestinal cells in C. elegans.36
In worms treated with Cy3-CB[7], only the pharynx was
stained after 12 h of incubation (Figure 3d). In a parallel
experiment with a different dye-conjugated CB[7], namely,
rhodamine X-conjugated CB[7] (ROX-CB[7]),37 we also
observed selective localization of ROX-CB[7] in the pharynx
of worms (Figure S5c, see the Supporting Information). When
worms were treated with Cy3-CB[7] whose portal was blocked
with 1-adamantaneamine, a substantially reduced fluorescence
signal in the pharynx was observed (Figure S7). These results
indicate the importance of the CB[7] moiety of dye-CB[7]s
(Cy3-CB[7] and ROX-CB[7]) for localization in C. elegans. In
another control experiment with free Cy3 and ROX instead of
Cy3-CB[7] and ROX-CB[7], respectively, free dyes did not
stain cells in the pharynx; rather, the former stained cells in the
intestine, and the latter did not stain any cells (Figure S6, see
the Supporting Information). These observations further
support a critical role for the CB[7] moiety in selective
staining of the pharynx by dye-CB[7]s. Importantly, dyes for
selective staining of the pharynx in C. elegans are not yet
commercially available. Thus, we used a transgenic C. elegans
strain (MIR8) expressing a green fluorescence protein (GFP)
fusion in the pharynx and body wall muscle38 to determine the
location of dyes by colocalization analysis. Both Cy3-CB[7]
and ROX-CB[7] signals overlapped well with GFP in the
pharynx (Figure S5b,c, see the Supporting Information),
suggesting that both dye-CB[7]s followed the same fate in
live C. elegans (i.e., localization in the pharynx).
Next, we investigated molecular recognition between CB[7]
and AdA in live C. elegans by sequential treatment with Cy3-
CB[7] and BDP630/650-AdA for 12 and 6 h, respectively. To
visualize FRET between Cy3-CB[7] and BDP630/650-AdA by
CLSM, emission signals from Cy3-CB[7] and BDP630/650-
AdA were collected through two different band path filters of
563−629 and 644−800 nm, respectively, upon irradiation with
the same excitation laser (555 nm for Cy3 excitation). Worms
treated with both sequentially displayed strong FRET signals
(Figure 3i), with a significantly reduced fluorescence intensity
for Cy3-CB[7] (Figure 3f) compared with worms treated only
with Cy3-CB[7] (Figure 3d), indicating molecular recognition
in live C. elegans. It is worth noting that FRET signals were
strong in the pharynx of worms in which Cy3-CB[7] had
already accumulated. After irradiating at the excitation
wavelength of BDP630/650 (639 nm), we observed
BDP630/650-AdA signals (Figure 3c) not only in the intestine
but also in the pharynx, which did not show accumulation of
BDP630/650-AdA when treated with BDP630/650-AdA alone
(Figure 3b). These results indicate that BDP630/650-AdA
recognized the prelocalized Cy3-CB[7] binding partner in the
pharynx of live worms. In other words, the localization for
BDP630/650-AdA was noncovalently anchored to prelocalized
Cy3-CB[7] in the pharynx through high binding affinity-based
in situ molecular recognition, similarly to natural protein-based
binding pairs such as antigen−antibody complexes.
To validate the pivotal role of chemical moieties between
CB[7] and AdA for the noncovalent anchoring in worms, we
performed a control experiment with Cy3-CB[7] and free
BDP630/650 without the AdA moiety following the same
procedures described above. The results revealed no FRET
signal and no change in the accumulation location of BDP630/
650 (Figure 4). Taken together, these results demonstrate the
Figure 3. CLSM images of C. elegans incubated with (a,d,g) Cy3-
CB[7] alone, (b,e,h) BDP630/650-AdA alone, and (c,f,i) Cy3-CB[7]
and BDP630/650-AdA, sequentially. (j−l) Bright field images
overlapped with (d,b,i), respectively. The focal plane for imaging
was in the middle of worms (with the focus at the midplane, Z = 9
μm).
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highly specific host−guest recognition between CB[7] and
AdA in vivo through spontaneous FRET from Cy3-CB[7] to
BDP630/650-AdA. Furthermore, it indicates supramolecular
latching of BDP630/650-AdA small guest molecule on the
pretreated Cy3-CB[7] host molecule in a live animal.
To confirm the above conclusion, we performed additional
C. elegans imaging under different treatment conditions using
the same FRET pair (Cy3-CB[7] and BDP630/650-AdA).
Motivated by gene transfection and drug delivery across cell
membranes following ultrasound stimulation that induces
temporal destabilization of cell membranes by microbubble
destruction (known as sonoporation)39−42 and the endurance
of C. elegans under ultrasound stimulation conditions,43 we
assumed that localization of Cy3-CB[7] would be altered by
ultrasound stimulation, which could in turn affect the
localization of BDP630/650-AdA by high-affinity-based supra-
molecular latching, as described above.
To validate this hypothesis, we first examined the local-
ization of Cy3-CB[7] following a pulsed ultrasound treatment
for 5 s (0.5 s per pulse) using a probe-type sonicator on live C.
elegans during incubation with Cy3-CB[7] (see Experimental
Section for details, Figures S9 and S10). It should be noted
that the ultrasound treatment that we performed in this study
did not appear to cause severe damage to the worms because
we did not detect any differences in movement or activity from
non-ultrasound-stimulated worms under an optical micro-
scope. CLSM revealed strong fluorescence signals for Cy3-
CB[7] not only in the pharynx but also under the cuticle layer
when the focal plane was in the middle (midplane, Z = 9 μm)
of live worms (Figure S8a, see the Supporting Information). By
adjusting the focal plane to the ventral side (ventral midline
plane, Z = 4 μm), allowing focused visualization on the C.
elegans epithelial system (skin) composed of an epidermis
(hypodermis) and an overlying cuticle,44 we observed a larger
number of fluorescent dots distributed throughout the entire
epithelial system (Figure S8b, see the Supporting Informa-
tion). These patterns and locations of the fluorescence signals
from Cy3-CB[7] were distinctly different from those of non-
ultrasound-stimulated worms that exhibited fluorescence
signals only in the pharynx (Figures 3 and 4d). These results
strongly suggest that ultrasound stimulation altered the
localization of Cy3-CB[7] in live C. elegans.
Interestingly, Cy3-CB[7] seemed to diffuse into the
epidermis across the cuticle layer during ultrasound
stimulation as a result of ultrasound stimulation to C. elegans
under four different Cy3-CB[7] incubation and washing
conditions (Figure S9, see the Supporting Information for
details); only when Cy3-CB[7] was located outside worms
(conditions 1 and 4 in Figure S9, see the Supporting
Information), Cy3-CB[7] was localized in the epithelial system
of worms. This suggests that Cy3-CB[7] was confined to the
pharynx and epidermis following digestive tract absorption and
ultrasound stimulation, respectively. Ultrasound stimulation
caused temporal destabilization of the cuticle layer, which
appeared to assist the diffusion of Cy3-CB[7] across the cuticle
barrier from outside.
In the case of BDP630/650-AdA, worms treated with
BDP630/650-AdA alone after ultrasound stimulation and
subsequently incubated for 6 h (Table S2) displayed
BDP630/650-AdA fluorescence in intestinal cells (Figure
5b), similar to those without ultrasound prestimulation (Figure
3b). This indicates that the ultrasound stimulation had an
Figure 4. CLSM images of C. elegans incubated sequentially with
(a,d,g) Cy3-CB[7] alone, (b,e,h) BDP630/650 alone, and (c,f,i) Cy3-
CB[7] and BDP630/650, sequentially. (j−l) Bright field images
overlapped with (d,b,i), respectively. The focal plane for imaging was
in the middle of worms.
Figure 5. CLSM images of C. elegans (a,d,g) treated with ultrasound
after Cy3-CB[7] incubation, (b,e,h) incubated with BDP630/650-
AdA after ultrasound treatment, and (c,f,i) treated as in (a,d,g) but
also with BDP630/650-AdA. (j−l) Bright field images overlapped
with (d,b,i), respectively. Focal planes for imaging were at the ventral
side (ventral midline plane, Z = 4 μm) and middle (midplane, Z = 9
μm) of the worms for (a,c,d,f,g,i) and (b,e,h), respectively (see the
Suppporting Information for details).
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insignificant effect on the fate of BDP630/650-AdA in live C.
elegans.
Next, we investigated the effect of supramolecular latching of
BDP630/650-AdA on altering the localization of Cy3-CB[7]
in live C. elegans using the FRET, as described above without
ultrasound stimulation. Consistent with the results shown in
Figure 3, BDP630/650-AdA still forms an in situ host−guest
complex with Cy3-CB[7]; there was a strong FRET signal at
the ventral midline plane near the epithelial system (Figure 5i).
Given that BDP630/650-AdA was localized in intestinal cells
when worms were treated with this alone (Figure 5b), the
localization of BDP630/650-AdA near the epithelial system in
ultrasound-stimulated worms further demonstrates noncova-
lent anchoring, supramolecular latching, of BDP630/650-AdA
(a small molecule) on prelocalized Cy3-CB[7] via specific and
stable in situ molecular recognition occurring in a complicated
live animal system.
Next, we extended this supramolecular latching tool to
higher animals such as mice to investigate its potential for in
vivo cancer imaging. For active localization of CB[7] units on a
cancer site in a mouse, the monocarboxylic acid-HEG
(hexaethylene glycol)-CB[7] derivative was conjugated to
Erbitux which is the trade name of cetuximab, a recombinant
chimeric monoclonal antibody that targets the human
epidermal growth factor receptor with high affinity for the
treatment of colorectal, neck, and lung cancers.45 Matrix-
assisted laser desorption/ionization time of flight mass
spectroscopy (MALDI-ToF MS) revealed successful conjuga-
tion of ca. five CB[7] units on Erbitux (Erbitux-CB[7]; Figure
S11). Prior to in vivo assessments, in vitro cell experiments
were performed to examine targeting ability of Erbitux after
CB[7] conjugation. Almost identical fluorescence signals for
the secondary antibody conjugated to Alexa 555 between both
groups of cancer cells treated with Erbitux-CB[7] and Erbitux
detected by CLSM (Figure 6b,c) and flow cytometry (Figure
6j) support that Erbitux retains its cancer cell targeting ability
after the conjugation. Supramolecular latching of Cy5-AdA31
to Erbitux-CB[7] on the cancer cells analyzed by CLSM
(Figure 6f) and flow cytometry (Figure 6k) additionally
supports not only conjugation of CB[7] units on Erbitux again
but also accessibility of the cavity of CB[7] units on Erbitux to
AdA using the ultrastable and bio-orthogonal host−guest
chemistry. In in vivo assessments with cancer-bearing mice,
only the mouse pretreated with Erbitux-CB[7] showed
selective accumulation of the Cy5-AdA on the cancer site
after intravenous injection of Cy5-AdA (Figure 7d). It clearly
demonstrates that Cy5-AdA can be noncovalently anchored on
Erbitux-CB[7] that is prelocalized in a cancer site in a live
mouse. This result was also cross-checked by detecting
distinguishably strong fluorescence signals of Cy5-AdA from
the extracted cancer tissues of the mouse treated with Erbitux-
CB[7] (Figure S12d). Taken together, this noncovalent in situ
anchoring, supramolecular latching, occurs efficiently under a
dynamic bloodstream condition, resulting in in vivo cancer
imaging of a mammalian model.
■ CONCLUSIONS
We have demonstrated a new supramolecular tool for
noncovalent in situ anchoring of small synthetic molecules in
live C. elegans using a fully synthetic high-affinity binding pair
consisting of Cy3-CB[7] and BDP630/650-AdA. Emergence
of FRET signals upon formation of an ultrastable host−guest
complex between them demonstrated specific host−guest
recognition in a complex biological environment inside live
animals. This synthetic system appears to behave similarly to
existing biological binding pairs such as antibody−antigen and
cytokine-receptor systems in terms of molecular recognition in
a complex environment. In addition, this synthetic system is
small (∼1 kDa), chemically robust and resistant to enzymatic
degradation, and bio-orthogonal in binding. Incorporating an
active functionality such as antibody to the synthetic host
molecule allows selective imaging of a cancer site in live mouse
by efficient in situ supramolecular latching of fluorescent dye-
conjugated synthetic guest molecule to prelocalized host
molecules on a cancer site. It clearly demonstrates the
potential of this supramolecular latching system for in vivo
cancer imaging. It is an example of in vivo applications of this
supramolecular latching system. Even so, the system has great
potential for incorporation of a wide variety of other
functionalities amenable to various biological and medical
Figure 6. (a−i) CLSM images of A549 cells: (I) no primary antibody
treated, but Cy5-AdA and second antibody-Alexa 555 treated, (II)
Erbitux, Cy5-AdA and second antibody-Alexa 555 treated, and (III)
Erbitux-CB[7], Cy5-AdA and second antibody-Alexa 555 treated, and
flow cytometry results of the cells under the conditions of I, II, and III
in the (j) Alexa 555 and (k) Cy5 channel.
Figure 7. In vivo fluorescence imaging of cancer-bearing mice (a)
untreated, (b) Cy5-AdA treated, (c) Erbitux and Cy5-AdA treated
sequentially, and (d) Erbitux-CB[7] and Cy5-AdA treated sequen-
tially.
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applications owing to its synthetic tractability for chemical
conjugation with not only other dyes and proteins as
demonstrated here but also carbohydrates and peptides. By
introducing a radioactive isotope to the small guest, this
supramolecular latching system can be exploited as a fast and
efficient tool for pretargeted immuno-positron emission
imaging and radionuclide therapy of cancers.46 These findings
may further provide insight into the development of new
chemical biological tools and medical therapeutic systems for
live animals.
■ EXPERIMENTAL SECTION
Synthesis of BDP630/650-AdA (Scheme S1). A solution of
AdA37 (8.5 mg) in anhydrous dimethyl sulfoxide (DMSO, 200 μL)
and triethylamine (2 μL) was added to BDP630/650 X NHS ester
(2.0 mg) in anhydrous DMSO (100 μL, Scheme S1, see the
Supporting Information). The mixture was stirred at room temper-
ature for 3 h. The final product (2 mg, 80%) was purified by high-
performance liquid chromatography and characterized by 1D and 2D
NMR (Figures S1 and S2). HR-ESI-MS (m/z): [M + H+] calcd for
[C45H57BF2N5O5S
+], 828.4136; found, 828.4122.
FRET Tests in Solution. The medium used for the FRET tests
was 1× PBS (Lonza, catalog #: BE17-516F, 6.7 mM PO4, without
calcium and magnesium) containing 3% BSA. The fluorescence
emission spectra of BDP630/650-AdA alone, Cy3-CB[7] alone, and a
mixture of both the compounds were scanned from 540 to 700 nm
with the same excitation wavelength (530 nm). For both compounds,
the final concentration was 500 nM. The percentage decrease of
fluorescence intensity from Cy3-CB[7] (donor) at 565 nm and the
percentage increase of fluorescence intensity from BDP630/650-AdA





















where PD is the percentage decrease of the donor at 565 nm, and IDA
and ID are the donor fluorescence intensities with and without the
acceptor, respectively. PA is the percentage increase of the acceptor at
646 nm; IAD and IA are the acceptor fluorescence intensities with and
without the donor, respectively.
C. elegans Culture. Two types of C. elegans (wild-type N2 and
GFP-expressed strain MIR8) were provided by Caenorhabditis
Genetics Center (CGC), University of Minnesota. Briefly, C. elegans
was cultured on solid nematode growth medium (NGM) plates and
fed with a lawn of OP50 (a uracil auxotrophic Escherichia coli strain
which grows slowly on NGM plates) or in liquid medium (S Medium
with concentrated OP50 as a food source) at room temperature. For
all the experiments, eggs of C. elegans were isolated in advance and
collected in M9 buffer and then incubated in liquid medium until the
L4 stage (28 h at 22 °C).
C. elegans Imaging with Individual FRET Compound.
Around 100 L4 stage worms were incubated in 200 μL of Cy3-
CB[7] (1 μM), ROX-CB[7] (1 μM), and BDP630/650-AdA (1 μM)
solution in liquid medium. After being incubated for a certain time
interval (12 h for the CB[7] derivatives and 6 h for BDP630/650-
AdA) on a gentle shaker (120 rpm min−1) at 22 °C, the worms were
washed 3 times with M9 buffer containing 0.01% Triton X-100 and
destained in liquid medium (6 h for CB[7] derivatives and 12 h for
BDP630/650-AdA). The worms were collected by centrifugation (1
min at 2000 rpm min−1) and then treated with anesthesia (4 mg mL−1
levamisole) in confocal dishes for live imaging. For the colocalization
of Cy3-CB[7] and ROX-CB[7] with GFP, a transgenic strain MIR8
was used instead of N2 strain.
Colocalization of BDP630/650-AdA with Lipid Droplet
Tracker. Around 100 L4 stage worms were incubated in 200 μL of
BDP630/650-AdA (1 μM) solution in liquid medium. After being
incubated for 6 h on a gentle shaker (120 rpm min−1) at 22 °C,
worms were washed 3 times with M9 buffer containing 0.01% Triton
X-100 to remove the remaining compound and then treated with 2
μM lipid droplet tracker BODIPY 493/503 for 12 h followed by
destaining in liquid medium for 6 h. Worms were washed and
collected by centrifugation and then treated with anesthesia (4 mg
mL−1 levamisole) in confocal dishes for live imaging.
Ultrasound-Assisted Internalization of Cy3-CB[7]. Around
100 L4 stage worms were incubated in 200 μL of Cy3-CB[7] (1 μM)
solution in liquid medium. Following incubation for 12 h on a gentle
shaker (120 rpm min−1) at 22 °C, the worms were exposed to pulsed
ultrasound stimulation by using a probe sonicator (20 W) with 20%
output power for 5 s (10 shots, 0.5 s per shot). The worms were
cultured for another 2 h followed by washing with M9 buffer
containing 0.01% Triton X-100 3 times and destained in liquid
medium for 18 h on a gentle shaker. The worms were collected by
centrifugation and then treated with anesthesia (4 mg mL−1
levamisole) in confocal dishes for live imaging. See Figure S10 for
the setup.
In Vivo Host−Guest Recognition Tests in Live C. elegans. L4
stage worms in liquid medium were evenly divided into four groups
(Table S1). The worms without any treatment were used as a blank.
The other three groups were treated as follows. (1) For worms treated
with both compounds sequentially, they were incubated in 400 μL of
Cy3-CB[7] (1 μM) in liquid medium for 12 h, washed with M9 buffer
containing 0.01% Triton X-100 3 times, and destained in liquid
medium for 6 h. Then, they were incubated in 400 μL of BDP630/
650-AdA (1 μM) in M9 buffer for 6 h, washed 3 times, and destained
in liquid medium for 12 h. (2) For the Cy3-CB[7]-treated group,
worms were incubated in 400 μL of Cy3-CB[7] (1 μM) in liquid
medium for 12 h, washed 3 times, and destained for 24 h. (3) For the
BDP630/650-AdA-treated group, worms were incubated in 400 μL of
liquid medium for 18 h and then in 400 μL of BDP630/650-AdA (1
μM) in liquid medium for 6 h. Then, the worms were washed 3 times
and destained for 12 h. After all the above treatments, the worms were
treated with anesthesia (4 mg mL−1 levamisole) in confocal dishes for
live imaging.
Synthesis of Monocarboxylic Acid-HEG-CB[7] (Scheme S2).
Monoallyloxy-functionalized CB[7] (300 mg, 246 μmol)31 and 1-
mercapto-3,6,9,12,15,18-hexaoxahenicosan-21-oic acid (SH-HEG-
COOH, 152 μL, 492 μmol) were added to H2O (3 mL) in a quartz
tube. After argon purging for 10 min, the mixtures were stirred for 12
h under UV light (254 nm) and dialyzed against H2O. After being
lyophilized, the product was obtained as a brown powder (200 mg,
51%). See the Supporting Information for 1H NMR (Figure S3) and
MALDI-ToF MS (Figure S4).
Synthesis of CB[7]-Conjugated Erbitux (CB[7]-Erbitux).
Monocarboxylic acid-HEG-CB[7] (72 μg, 55 nmol) was added in a
solution of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (90 μg,
550 nmol) and N-hydroxysulfosuccinimide (180 μg, 2 μmol) in
phosphate buffer silane (350 μL) and stirred for 12 h at room
temperature. To the mixture, Erbitux (100 μg, 670 pmol) was added
and kept at 4 °C for 2 d. CB[7]-Erbitux was obtained by washing with
PBS through centrifugal filtration (MWCO: 100 kDa). Successful
conjugation was confirmed by MALDI-ToF MS (Figure S11).
Immunofluorescence Imaging Using A549 Cells. A549 cells
(1 × 105) were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Hyclone) containing 10% fetal bovine serum (FBS,
Hyclone) and 1% penicillin and streptomycin, and were transferred
onto each confocal dish and incubated for 24 h. Erbitux or Erbitux-
CB[7] (2 μg each) in 1 mL of DMEM containing 10% FBS and 1%
penicillin−streptomycin (PS) was added to the cells. After 30 min of
incubation in a humidified 5% CO2 atmosphere at 37 °C, the cells
were washed with PBS and treated with Alexa 555-labeled antihuman
second antibody (2 μg) in 1 mL of DMEM. After 30 min of
incubation at the incubator, the cells were washed with PBS and
treated with Cy5-AdA in DMEM (200 nM, 1 mL). After incubation
for 30 min at the incubator, cells were washed with PBS and added in
DMEM (1 mL), and fluorescence intensity of each sample was
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visualized by CLSM with excitation at 488 and 633 nm for Alexa 555
and Cy5, respectively.
Flow Cytometry. A549 cells (1 × 106) in DMEM (1 mL)
containing 10% FBS and 1% PS were transferred to a centrifuge tube.
Erbitux or Erbitux-CB[7] (2 μg each) in 1 mL of DMEM containing
10% FBS and 1% PS was added to the cells. After 30 min of
incubation in a humidified 5% CO2 atmosphere at 37 °C, the cells
were washed with PBS (1 mL) for 3 times. Additionally, the same
process was carried out with Cy5-AdA in DMEM (200 nM, 1 mL)
and Alexa 555-labeled antihuman secondary antibody (2 μg) in 1 mL
of DMEM, sequentially. Finally, the cells were resuspended with 200
μL of PBS and analyzed by using a flow cytometry machine with
excitation at 488 and 633 nm for Alexa 555 and Cy5, respectively.
Preparing Cancer-Bearing Mice. All the animal experiments
were conducted with appropriate permission from the animal rights
commission of the Advanced Bio Convergence Center, Pohang
Technopark Foundation. A549 cells were inoculated subcutaneously
(s.c.) at a density of 1 × 107 cells per mouse into the flank of each
female balb/c mouse weighing 20 g. The cancer cells inoculated were
left for approximately 3 weeks until the tumors reached 5−10 mm in
size.
In Vivo Imaging of Cancer on Mice. The mice were randomly
divided into four groups and intravenously injected with PBS (200
μL), Erbitux (100 μg in 200 μL of PBS), or CB[7]-Erbitux (100 μg in
200 μL of PBS). After 24 h of injection, PBS (200 μL) or Cy5-AdA
(200 μL, 200 nM in PBS) was injected to the mice. After 6 h of
uptake, whole body imaging and ex vivo imaging were performed and
analyzed with an IVIS spectrum small-animal in vivo imaging system
(Caliper Life Sciences).
Biodistribution of Cy5-AdA and Region of Interest Values
of Cy5-AdA from Extracted Organs. After the final imaging, mice
(n = 3) were sacrificed, and major organs (tumor, muscle, spleen,
liver, kidney, heart, and lung) were collected for detecting
fluorescence signals of Cy5-AdA by using the IVIS machine (ex. =
640 nm, em. = 700 nm). The radiance (photon emission per unit
area) of a region of interest in each organ was acquired by using
ImageJ software (Figure S12).
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